Related Experiment Video
Updated: May 23, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Novel N-hydroxybenzamide histone deacetylase inhibitors as potential anti-cancer agents
1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, China.
Abstract:
Histone deacetylases (HDACs) are a class of Zn(2+) dependent metalloproteases that play an important role in tumorigenesis. Inhibition of HDACs may be a potential strategy for cancer therapy. This study designed and synthesized a series of novel N-hydroxybenzamide histone deacetylase inhibitors based on the structural features of suberoylanilide hydroxamic acid (SAHA), the first HDAC inhibitor that came to market. Preliminary biological evaluation in vitro found that most of the inhibitors had satisfactory inhibitory activity (IC(50) =1-17 μM) against HDACs and HCT116 tumor cells.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Inhibition of Cdk Activity
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Histone Variants at the Centromere

